GlassScriptPhysician profile
Stacy Lane
NPI 1568681336
$5,716.39
in general payments reported to CMS, 2019-2025
22 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,356 · 2020: $742 · 2021: $1,085 · 2022: $796 · 2023: $949 · 2024: $589 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,737.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,323.31 | 2019-2025 | Cabenuva, Apretude |
| Gilead Sciences, INC. | $1,405.88 | 2019-2025 | Biktarvy |
| Abbvie INC. | $702.68 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $305.01 | 2019-2022 | |
| Indivior INC. | $262.21 | 2019-2022 | |
| Antares Pharma, INC. | $121.64 | 2022 | |
| Theratechnologies INC. | $107.92 | 2019-2022 | |
| Emd Serono, INC. | $90.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $85.38 | 2020-2021 | |
| Janssen Biotech, INC. | $66.26 | 2023 | Symtuza |
| Hologic Sales and Service, LLC | $37.55 | 2025 | Aptima |
| Neurocrine Biosciences, INC. | $28.70 | 2019 | |
| Paratek Pharmaceuticals, INC. | $26.39 | 2019 | |
| Alkermes, INC. | $23.53 | 2021 | |
| Mayne Pharma Commercial LLC | $20.67 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $19.92 | 2019 | |
| Lilly USA, LLC | $18.85 | 2019 | |
| Mylan Institutional INC. | $18.22 | 2019 | |
| Sunovion Pharmaceuticals INC. | $15.93 | 2019 | |
| Vyera Pharmaceuticals, LLC | $12.82 | 2019 | |
| Metuchen Pharmaceuticals | $11.70 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.